Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

Neuromuscular Diseases

An Introduction to Neuromuscular Diseases

Supported by:
EUROPEAN PARTNER
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Carolina Barnett-Tapia, Prof. Nils Erik Gilhus

Watch experts discuss strategies to accelerate MG diagnosis and treatment, plus consider emerging therapies.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

54 mins
Sponsored Content

Watch leading experts discuss the use of neurofilament levels as a potential marker in ALS and SMA.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

Mark CompleteCompleted
BookmarkBookmarked

Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

29 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Prof. Michael Nicolle, Dr Karissa Gable, Ms Missy Pittman

Watch three experts discuss the role of FcRn inhibitors in the management of generalized myasthenia gravis

22 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: USA

Watch a leading expert discuss the key signs and symptoms of Friedreich ataxia and how to avoid diagnostic delays.

64 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS
Prof. Tahseen Mozaffar, Dr Jennifer L Cohen, Prof. Benedikt Schoser

Leading experts in Pompe disease explore key data from WMS 2024 and WORLDSymposium 2025.

Mark CompleteCompleted
BookmarkBookmarked

Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.

4 mins
Sponsored Content

Watch this short video animation to learn how genetic mutations in patients with Friedreich ataxia (FA) translate into clinical symptoms.

Mark CompleteCompleted
BookmarkBookmarked

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ...

Mark CompleteCompleted
BookmarkBookmarked

The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.

47 mins
Sponsored Content

Learn from leading genetic counsellors on how to integrate the ALS genetic counseling and testing guidelines into clinical practice.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.

49 mins
Sponsored Content

Watch leading spinal muscular atrophy (SMA) experts discuss current trends in pharmacologic and non-pharmacologic therapy use, barriers to use of these standards of care, and potential solutions to improve access as patients age.

Coverage from: EAN 2024

Myasthenia gravis (MG) is an autoimmune disorder where antibodies disrupt the neuromuscular junction, causing muscle weakness that worsens with activity. MG subgroups are based on muscle weakness location, age, antibody type, and thymus pathology, with some patients experiencing severe, treatment-resistant symptoms. Biomarkers can indicate prognosis. First-line treatments include pyridostigmine for symptomatic relief and immunosuppressants like prednisolone and azathioprine. Thymectomy is recommended for certain patients. Second-line treatments include mycophenolate, rituximab, and others, with new therapies like complement and FcRn inhibitors showing promise. Intravenous immunoglobulin and plasma exchange are used for acute exacerbations. Supportive therapy, including adapted exercise, is crucial. In refractory cases, comorbidities and diagnosis accuracy should be reconsidered.

49 mins
Sponsored Content

Learn about the latest advancements and current barriers in genetic counseling and testing from expert speaker, Jennifer Roggenbuck.

Load More...
Close Popup